Research and Markets: Generic Pharmaceutical Litigation: Legislation leading to Healthy Competition between Pioneer and Generic Drug Manufacturers

Dublin-- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Generic Pharmaceutical Litigation to their offering.

(PRWEB) October 4, 2004 -- With US pharmaceutical revenues reaching almost $200B and average drug prices growing over 7% annually, generic drugs are being viewed as the low-cost remedy for rising national healthcare spending. Congress has legislated incentives for both pioneer and generic manufacturers, and this has resulted in healthy competition, which benefits the consumer. Already, 50% of prescriptions are filled with generic drugs, and this number is expected to increase to 58% by 2006.

Pioneer drug manufacturers are facing increased generic threats to their best sellers. Paragraph IV Abbreviated New Drug Applications are published for 11 drugs with annual revenues above $1B, and patent litigation is ongoing in most instances. Historically, brand name drug companies have been successful at maintaining exclusivity in only about 30% of cases.

This report includes in-depth analysis with management perspectives and incorporates a cost-benefit analysis of litigation outcomes. Assessments of the trends, challenges, and strategic options facing brand as well as generic pharmaceutical companies are also covered in detail. This analysis is laid onto a framework of US and international legislation governing the drug industry, and presents a timeline of the passage of key regulations.

For a thorough analysis of this important trend, the report:

- Highlights the key regulations that cover generic drugs and places them in the overall context of drug development and governing legislation

- Summarizes regulation around the world

- Incorporates perspectives from manufacturers and patent attorneys

- Evaluates the outcomes of litigation with detailed assumptions about factors affecting revenue

- Reviews results from cases involving litigation over generic competition

- Identifies multiple trends affecting litigation and challenges facing manufacturers

- Provides strategic options for brand and generic pharmaceutical companies looking to expand their revenues

Report Contents:

I. Executive Summary

II. Objectives and Methodology

III. Legislation Overview

IV. Generic Litigation Impact Analysis

VI. Strategic Options

For more information visit http://www.researchandmarkets.com/reports/c5720